HIV-1 and bacterial pneumonia in the era of antiretroviral therapy

Proceedings of the American Thoracic Society

Volumn 8, Issue 3, 2011, Pages 282-287

  Segal, Leopoldo N ^a   Methé, Barbara A ^b   Nolan, Anna ^a   Hoshino, Yoshihiko ^a   Rom, William N ^a   Dawson, Rod ^c   Bateman, Eric ^c   Weiden, Michael D ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b J CRAIG VENTER INSTITUTE   (United States)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Bacterial pneumonia; HIV antiretroviral therapy

Indexed keywords

ANTIRETROVIRUS AGENT; BACTERIAL DNA; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PNEUMOCOCCUS VACCINE; RIBOSOME DNA; TUMOR NECROSIS FACTOR ALPHA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; B LYMPHOCYTE; BACTERIAL PNEUMONIA; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL FUNCTION; COMAMONADACEAE; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CYTOKINE PRODUCTION; DNA SEQUENCE; ENTEROBACTERIACEAE; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNIZATION; INNATE IMMUNITY; LUNG ALVEOLUS CELL; LUNG ALVEOLUS MACROPHAGE; LUNG TUBERCULOSIS; MORAXELLACEAE; NEUTROPHIL; OPPORTUNISTIC INFECTION; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCACEAE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VIRUS REPLICATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; BACTERIA; BRONCHOALVEOLAR LAVAGE FLUID; CD4 LYMPHOCYTE COUNT; COMMUNITY-ACQUIRED INFECTIONS; DNA, RIBOSOMAL; HIV INFECTIONS; HIV-1; HUMANS; LUNG; NEUTROPHILS; PNEUMONIA, BACTERIAL; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 80051738661     PISSN: 15463222     EISSN: 19435665     Source Type: Journal    
DOI: 10.1513/pats.201006-044WR     Document Type: Conference Paper

References (43)

1. Park D.R., Sherbin V.L., Goodman M.S., Pacifico A.D., Rubenfeld G.D., Polissar N.L., Root R.K. The etiology of community-acquired pneumonia at an urban public hospital: influence of human immunodeficiency virus infection and initial severity of illness. J Infect Dis 2001;184:268-277. (Pubitemid 32662172)
2. Grubb J.R., Moorman A.C., Baker R.K., Masur H. The changing spectrum of pulmonary disease in patients with HIV infection on antiretroviral therapy. AIDS 2006;20:1095-1107. (Pubitemid 43786097)
3. Schwarcz S., Hsu L., Dilley J.W., Loeb L., Nelson K., Boyd S. Late diagnosis of HIV infection: trends, prevalence, and characteristics of persons whose HIV diagnosis occurred within 12 months of developing AIDS. J Acquir Immune Defic Syndr 2006;43:491-494. (Pubitemid 44737109)
4. Hirschtick R.E., Glassroth J., Jordan M.C., Wilcosky T.C., Wallace J.M., Kvale P.A., Markowitz N., Rosen M.J., Mangura B.T., Hopewell P.C. Pulmonary Complications of HIV Infection Study Group. Bacterial pneumonia in persons infected with the human immunodeficiency virus. N Engl J Med 1995;333:845-851.
5. Weverling G.J., Mocroft A., Ledergerber B., Kirk O., Gonzales-Lahoz J., d'Arminio Monforte A., Proenca R., Phillips A.N., Lundgren J.D., Reiss P. Eurosida Study Group. Discontinuation of pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. Lancet 1999;353:1293-1298. (Pubitemid 29178778)
6. Lopez Bernaldo de Quiros J.C., Miro J.M., Pena J.M., Podzamczer D., Alberdi J.C.,Martinez E., Cosin J., ClaramonteX., Gonzalez J., Domingo P., et al.A randomized trial of the discontinuation of primary and secondary prophylaxis against pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. N Engl J Med 2001;344:159-167. (Pubitemid 32064136)
7. Ledergerber B., Mocroft A., Reiss P., Furrer H., Kirk O., Bickel M., Uberti-Foppa C., Pradier C., D'Arminio Monforte A., Schneider M.M., et al. Discontinuation of secondary prophylaxis against pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. N Engl J Med 2001;344:168-174. (Pubitemid 32064137)
8. WHO. Global tuberculosis control: a short update to the 2009 report. World Health Organization; 2009.
9. Kohli R., Lo Y., Homel P., Flanigan T.P., Gardner L.I., Howard A.A., Rompalo A.M., Moskaleva G., Schuman P., Schoenbaum E.E. Bacterial pneumonia, HIV therapy, and disease progression among HIVinfected women in the HIV epidemiologic research (her) study. Clin Infect Dis 2006;43:90-98. (Pubitemid 43939081)
10. Sullivan J.H., Moore R.D., Keruly J.C., Chaisson R.E. Effect of antiretroviral therapy on the incidence of bacterial pneumonia in patients with advanced HIV infection. Am J Respir Crit Care Med 2000;162:64-67. (Pubitemid 30469799)
11. Grau I., Pallares R., Tubau F., Schulze M.H., Llopis F., Podzamczer D., Linares J., Gudiol F. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med 2005;165:1533-1540. (Pubitemid 41058035)
12. Wallace J.M., Hansen N.I., Lavange L., Glassroth J., Browdy B.L., Rosen M.J., Kvale P.A., Mangura B.T., Reichman L.B., Hopewell P.C. Pulmonary Complications of HIV Infection Study Group. Respiratory disease trends in the pulmonary complications of HIV infection study cohort. Am J Respir Crit Care Med 1997;155:72-80. (Pubitemid 27053144)
13. Dworkin M.S., Ward J.W., Hanson D.L., Jones J.L., Kaplan J.E. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis 2001;32:794-800. (Pubitemid 32221939)
14. Heffernan R.T., Barrett N.L., Gallagher K.M., Hadler J.L., Harrison L.H., Reingold A.L., Khoshnood K., Holford T.R., Schuchat A. Declining incidence of invasive streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. J Infect Dis 2005;191:2038-2045. (Pubitemid 40800574)
15. El-Sadr W.M., Lundgren J.D., Neaton J.D., Gordin F., Abrams D., Arduino R.C., Babiker A., Burman W., Clumeck N., Cohen C.J., et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-2296. (Pubitemid 44837777)
16. Osmond D.H., Chin D.P., Glassroth J., Kvale P.A., Wallace J.M., Rosen M.J., Reichman L.B., Poole W.K., Hopewell P.C. Pulmonary Complications of HIV Study Group. Impact of bacterial pneumonia and pneumocystis carinii pneumonia on human immunodeficiency virus disease progression. Clin Infect Dis 1999;29:536-543. (Pubitemid 29439949)
17. Whalen C., Horsburgh C.R., Hom D., Lahart C., Simberkoff M., Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 1995;151:129-135.
18. Lundgren J.D., Babiker A., El-Sadr W., Emery S., Grund B., Neaton J.D., Neuhaus J., Phillips A.N. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the smart study: role of CD4+ cell counts and HIV RNA levels during follow-up. J Infect Dis 2008;197:1145-1155. (Pubitemid 351590050)
19. Gordin F.M., Roediger M.P., Girard P.M., Lundgren J.D., Miro J.M., Palfreeman A., Rodriguez-Barradas M.C., Wolff M.J., Easterbrook P.J., Clezy K., et al. Pneumonia in HIV-infected persons: increased risk with cigarette smoking and treatment interruption. Am J Respir Crit Care Med 2008;178:630-636.
20. Elssner A., Carter J.E., Yunger T.M., Wewers M.D. HIV-1 infection does not impair human alveolar macrophage phagocytic function unless combined with cigarette smoking. Chest 2004;125:1071-1076. (Pubitemid 38367303)
21. Mizgerd J.P. Acute lower respiratory tract infection. N Engl J Med 2008;358:716-727.
22. Takahashi H., Oishi K., Yoshimine H., Kumatori A., Moji K., Watanabe K., Nalwoga H., Tugume S.B., Kebba A., Mugerwa R., et al. Decreased serum opsonic activity against streptococcus pneumoniae in human immunodeficiency virus-infected Ugandan adults. Clin Infect Dis 2003;37:1534-1540. (Pubitemid 37494683)
23. Titanji K., De Milito A., Cagigi A., Thorstensson R., Grutzmeier S., Atlas A., Hejdeman B., Kroon F.P., Lopalco L., Nilsson A., et al. Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood 2006;108:1580-1587. (Pubitemid 44316125)
24. Twigg H.L., Soliman D.M., Day R.B., Knox K.S., Anderson R.J., Wilkes D.S., Schnizlein-Bick C.T. Lymphocytic alveolitis, bronchoalveolar lavage viral load, and outcome in human immunodeficiency virus infection. Am J Respir Crit Care Med 1999;159:1439-1444. (Pubitemid 29227851)
25. Douek D.C., Brenchley J.M., BettsM.R.,Ambrozak D.R.,Hill B.J., Okamoto Y., Casazza J.P., Kuruppu J., Kunstman K., Wolinsky S., et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002;417:95-98. (Pubitemid 34498823)
26. Orenstein J.M., Fox C., Wahl S.M. Macrophages as a source of HIV during opportunistic infections. Science 1997;276:1857-1861.
27. Kwon D.S., Gregorio G., Bitton N., Hendrickson W.A., Littman D.R. DC-sign-mediated internalization of HIV is required for trans-enhancement of T cell infection. Immunity 2002;16:135-144. (Pubitemid 34143223)
28. Beck J.M. The immunocompromised host: HIV infection. Proc Am Thorac Soc 2005;2:423-427.
29. Twigg H.L., Weiden M., Valentine F., Schnizlein-Bick C.T., Bassett R., Zheng L., Wheat J., Day R.B., Rominger H., Collman R.G., et al. Effect of highly active antiretroviral therapy on viral burden in the lungs of HIV-infected subjects. J Infect Dis 2008;197:109-116. (Pubitemid 351263474)
30. Descombes P., Schibler U. A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA. Cell 1991;67:569-579. (Pubitemid 121001471)
31. Henderson A.J., Calame K.L. CCAAT/enhancer binding protein (C/EBP) sites are required for HIV-1 replication in primary macrophages but not CD4(+) T cells. Proc Natl Acad Sci USA 1997;94:8714-8719. (Pubitemid 27335105)
32. Honda Y., Rogers L., Nakata K., Zhao B.Y., Pine R., Nakai Y., Kurosu K., Rom W.N., Weiden M. Type 1 interferon induces inhibitory 16-kd CCAAT/ enhancer binding protein (C/EBP)beta, repressing the HIV-1 long terminal repeat in macrophages: pulmonary tuberculosis alters C/EBP expression, enhancing HIV-1 replication. J Exp Med 1998;188:1255-1265. (Pubitemid 28478014)
33. Hoshino Y., Nakata K., Hoshino S., Honda Y., Tse D.B., Shioda T., Rom W.N., Weiden M. Maximal HIV-1 replication in alveolar macrophages during tuberculosis requires both lymphocyte contact and cytokines. J Exp Med 2002;195:495-505. (Pubitemid 34461302)
34. Hoshino Y., Hoshino S., Gold J.A., Raju B., Prabhakar S., Pine R., Rom W.N., Nakata K., Weiden M. Mechanisms of polymorphonuclear neutrophil-mediated induction of HIV-1 replication in macrophages during pulmonary tuberculosis. J Infect Dis 2007;195:1303-1310. (Pubitemid 46649615)
35. Hoshino Y., Tse D.B., Rochford G., Prabhakar S., Hoshino S., Chitkara N., Kuwabara K., Ching E., Raju B., Gold J.A., et al. Mycobacterium tuberculosis-induced CXCR4 and chemokine expression leads to preferential X4 HIV-1 replication in human macrophages. J Immunol 2004;172:6251-6258. (Pubitemid 38621231)
36. Lin H.H., Ezzati M., Chang H.Y., Murray M. Association between tobacco smoking and active tuberculosis in Taiwan: prospective cohort study. Am J Respir Crit Care Med 2009;180:475-480.
37. Zolopa A., Andersen J., Powderly W., Sanchez A., Sanne I., Suckow C., Hogg E., Komarow L. Early antiretroviral therapy reduces aids progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS ONE 2009;4:e5575.
38. Abdool Karim S.S., Naidoo K., Grobler A., Padayatchi N., Baxter C., Gray A., Gengiah T., Nair G., Bamber S., Singh A., et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010;362:697-706.
39. Velasco M., Castilla V., Sanz J., Gaspar G., Condes E., Barros C., Cervero M., Torres R., Guijarro C. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr 2009;50:148-152.
40. Wilkinson K.A., Seldon R., Meintjes G., Rangaka M.X., Hanekom W.A., Maartens G., Wilkinson R.J. Dissection of regenerating T-cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis. Am J Respir Crit Care Med 2009;180:674-683.
41. Bourgarit A., Carcelain G., Martinez V., Lascoux C., Delcey V., Gicquel B., Vicaut E., Lagrange P.H., Sereni D., Autran B. Explosion of tuberculinspecific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 2006;20:F1-F7.
42. Weiden M., Tanaka N., Qiao Y., Zhao B.Y., Honda Y., Nakata K., Canova A., Levy D.E., Rom W.N., Pine R. Differentiation of monocytes to macrophages switches the Mycobacterium tuberculosis effect on HIV-1 replication from stimulation to inhibition: modulation of interferon response and CCAAT/enhancer binding protein beta expression. J Immunol 2000;165:2028-2039. (Pubitemid 30643152)
43. Tanaka N., Hoshino Y., Gold J., Hoshino S., Martiniuk F., Kurata T., Pine R., Levy D., Rom W.N., Weiden M. Interleukin-10 induces inhibitory C/EBP beta through Stat-3 and represses HIV-1 transcription in macrophages. Am J Respir Cell Mol Biol 2005;33:406-411. (Pubitemid 41416292)